동남아시아 분자적 진료 시점 테스트(NAAT 사용) 시장 – 2028년까지의 산업 동향 및 예측

동남아시아 분자적 진료 시점 테스트(NAAT 사용) 시장 분석 및 통찰력

동남아시아 분자적 진료 시점 검사(NAAT 사용) 시장은 의료 시설과 인프라 개선과 병원, 실험실, 진료소에서 진료 시점 검사 도입으로 인해 성장할 것으로 예상되며, 이는 시장 성장을 촉진할 수 있습니다. 분자적 진료 시점 검사(NAAT 사용) 시장 성장을 촉진할 것으로 예상되는 다른 요인으로는 감염성 질환의 유병률 증가가 있습니다.

숙련된 전문가의 부족과 맞춤형 분자적 진료 시점 검사(NAAT 사용)의 높은 비용과 같은 다른 요인은 동남아시아 분자적 진료 시점 검사(NAAT 사용) 시장의 성장을 방해합니다. 반면, 의료비 지출 증가와 선진 병원이 있는 신흥국은 동남아시아 분자적 진료 시점 검사(NAAT 사용) 시장을 성장시킬 수 있는 기회로 작용합니다.

Data Bridge Market Research는 동남아시아 분자적 진료 시점 테스트(NAAT 사용) 시장이 2021년부터 2028년까지 연평균 성장률 8.9%로 성장할 것으로 분석했습니다.

동남아시아 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장의 시장 정의

POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30cm x 30cm. These instruments are essentially used in molecularly detecting various disorders such as HIV, HPV, and respiratory disease through NAAT technology. NAAT is Nucleic Acid Amplification Techniques that allow the identification of pathogenic organisms by detecting their DNA or RNA.

In the worldwide pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propelled the growth of the market.

South East Asia Molecular Point of Care Testing (using NAAT) Market Dynamics

 This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• INCREASE PREVALENCE OF CHRONIC DISEASES

It is a common fact that health degeneration starts with an increase in age. As the rate of chronic disease grows with time, the factors associated with the disease rates also increase. The high number of obese/ overweight population also has increased the prevalence of chronic diseases in various regions across the globe. The rise in the number of chronic diseases similar to HPV, STI, and TB, among more, has led to people opting for NAAT-based point-of-care and products for testing. Therefore, this will drive the growth of the South East Asia Molecular point of care testing (using NAAT) market in the coming years.

• IMPROVEMENT IN DIAGNOSIS-SEEKING RATE

With the increase in the successful diagnosis of chronic diseases, including cancer, anemia, type 2 diabetes, and others, the improved health care professionals provide regular training sessions for the professionals for conducting tests in account for the improvement of diagnosis rate in the region. With the increase in the burden of diseases, the diagnosis rate is also increasing. With the advancements in the diagnosis, the rate is also growing for people going through the diagnosis.

• RISE IN PREFERENCE FOR HOMECARE TESTING

Home healthcare preferences make clinical information available at the right place and time. It will also help in reducing error and increasing safety with ensured quality. They also help elders in the case of a medical emergency. There have been many strategic changes done in health care to address point-of-care testing benefits. As per the World Health Organization (WHO), the number of people aged 65 and above is expected to rise from an estimated 524 million in 2010 to approximately 1.5 billion in 2050, with developed countries accounting for the majority of the increase.

Opportunities

• STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

An increase in the burden of chronic and non-chronic disease globally coupled with the rise in the geriatric population in Africa and Asia has created more demand for the development of new kits and solutions for molecular point-of-care testing with better efficacy and less time consumption. To provide diagnosis and screening in this region, the players in the market undergo partnership and agreement with each other to provide quality care through kits and instruments to the South East Asia population.

• RisE Healthcare Expenditure

Increasing healthcare expenditure and infrastructure can help patients take hassle-free advanced treatment to receive better diagnoses, procedures, and treatment for fast recovery. Point-of-care testing devices are beneficial for detecting various diseases and supporting treatment plans using POC software and solutions. Healthcare spending comprises out-of-pocket payments (people paying for their care), government expenditure, and sources including health insurance and activities by non-governmental organizations.

Restraints/Challenges

• HIGH COST OF PRODUCTS

The point-of-care testing products require a substantial considerable cost for the development process. As the concept needs to be locked down, the materials must be sourced, and it is essential to consider lead times. Additionally, the process is time-consuming as the device design needs sufficient time to fully mature before bringing to the market for use.

• LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

When compared with the results of laboratory testing standards, the NAAT testing results differ. Laboratory testing is more advanced, follows the process, protocol, and science for laboratory testing, and fully integrates with the technology necessary to analyze, validate, and accurately document effects. However, POCT/NAAT is undoubtedly associated with a lack of precise results. Molecular POCT cannot complete the standardization, and other critical criteria cannot achieve the standardization and different essential standards. It is a significant challenge for the South East Asia Molecular point of care testing market. The PoC tests might sometimes provide erroneous results and suffers test results variability.

Post-COVID-19 Impact on South East Asia Molecular Point of Care Testing (using NAAT) Market

COVID-19 significantly impacted the molecular point of care testing (using NAAT) market. COVID-19 has positively affected the price and demand of molecular point of care testing (using NAAT) products at a higher level because of progressive online sales and technological advancements. The COVID-19 pandemic outbreak positively impacted the market's growth owing to the increased requirement for molecular point of care testing (using NAAT), especially in various hospitals. The current priority in most hospitals is given to COVID-19 treatments as the surge of COVID-19 cases is still persistent, which also increases the usage of molecular point of care testing (using NAAT). Moreover, many international governments and healthcare organizations have supported the supply of these products due to their high priority in crucial cases.

Recent Developments

• In November 2021, F.Hoffmann-La Roche Ltd announced that Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year. This increased the business doing capacity and business expansion in the forecast period
• In October 2021, Thermo Fisher Scientific Corporation received FDA approval for the TaqMan COVId-19 test SARS-COV molecular Assay. This increased the product portfolio of the company and contributed to the company revenue in the forecast period

South East Asia Molecular Point of Care Testing (using NAAT) Market Scope

South East Asia molecular point of care testing (using NAAT) market is categorized into five notable segments based on the product, indication, end user, mode of testing, and distribution channel. The growth amongst these segments will help to analyze market growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Instruments
• Consumables and Reagents

Based on product, the South East Asia molecular point of care testing (using NAAT) market is segmented into instruments and consumables and reagents.

Indication

• Sexually Transmitted Infection (STI) Testing
• Respiratory Infection Testing
• Gastrointestinal Tract Infection Testing
• Others

Based on indication, the South East Asia molecular point of care testing (using NAAT) market is segmented into sexually transmitted infection (STI) testing, respiratory infection testing, gastrointestinal tract infection testing, and others.

End User

• Laboratories
• Hospitals
• Clinics
• Ambulatory Centers
• Home Care
• Assisted Living Facilities
• Others

Based on End User, the South East Asia molecular point of care testing (using NAAT) market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, and others.

Mode of Testing

• Prescription-Based Testing
• OTC Testing

Based on testing mode, the South East Asia molecular point of care testing (using NAAT) market is segmented into prescription-based and OTC testing.

유통 채널

• 병원 약국
• 소매 약국
• 온라인 약국

동남아시아 분자적 진료 시점 검사(NAAT 사용) 시장은 유통 채널을 기준으로 병원 약국, 소매 약국, 온라인 약국으로 구분됩니다.

동남아시아 분자적 진료 시점 테스트(NAAT 사용) 시장 지역 분석/통찰력

동남아시아 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장을 분석합니다. 제품, 적응증, 최종 사용자, 테스팅 모드, 유통 채널을 기반으로 시장 규모 통찰력과 추세를 제공합니다.

동남아시아 분자적 진료 시점 검사(NAAT 사용) 시장 보고서는 싱가포르, 베트남, 태국, 말레이시아, 인도네시아, 필리핀 및 기타 동남아시아 지역을 포괄합니다.

싱가포르는 시장 점유율과 시장 수익 측면에서 동남아시아 분자적 진료 시점 검사(NAAT 사용) 시장을 지배하고 있습니다. 예측 기간 동안에도 지배력을 계속 유지할 것입니다. 이는 감염성 및 만성 질환의 유병률이 증가하고 의료 분야의 기술 발전이 증가하고 있기 때문입니다.

경쟁 환경 및 동남아시아 분자적 진료 시점 테스트(NAAT 사용) 시장 점유율 분석

동남아시아 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 구성 요소는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 동남아시아 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 규제 지침, 브랜드 분석, 제품 승인, 제품 탑재량, 애플리케이션 우세, 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 동남아시아 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장에 대한 회사의 초점에만 관련이 있습니다.

동남아시아 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장에서 운영되는 주요 기업 중 일부는 Thermo Fisher Scientific Inc., Hologic, Inc., Seegene Inc., SD Biosensor, INC., Sysmex Corporation, Sekisui Diagnostics, Wondfo, F. Hoffmann-La Roche Ltd, bioMérieux SA, Grifols, SA, Danaher 등입니다.

SKU-66924